For the treatment of patients with severe hypercholesterolemia, specific interventions were developed such as lomitapide (a small molecule inhibitor of microsomal triglyceride transfer protein) that was approved for the treatment of homozygous familial hypercholesterolemia in 2012 in North America and Europe [60]. Here, MTTP is linked to Hypercholesterolemia.